Last reviewed · How we verify
r-LH supplementation
Recombinant luteinizing hormone (r-LH) supplementation replaces or augments endogenous LH to stimulate testosterone production and support follicle development in reproductive disorders.
Recombinant luteinizing hormone (r-LH) supplementation replaces or augments endogenous LH to stimulate testosterone production and support follicle development in reproductive disorders. Used for Infertility in women undergoing assisted reproductive technology (ART), Hypogonadotropic hypogonadism in males, Anovulation and ovulatory disorders in women.
At a glance
| Generic name | r-LH supplementation |
|---|---|
| Also known as | luveris |
| Sponsor | Sisli Hamidiye Etfal Training and Research Hospital |
| Drug class | Gonadotropin |
| Target | LH receptor (LHCGR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Endocrinology / Fertility |
| Phase | FDA-approved |
Mechanism of action
r-LH is a recombinant form of the pituitary gonadotropin that binds to LH receptors on Leydig cells (in males) and theca cells (in females) to promote sex steroid synthesis. In males, it stimulates testosterone production; in females, it supports estrogen synthesis and ovulation. It is typically used in combination with FSH in assisted reproductive technology or in hypogonadotropic hypogonadism.
Approved indications
- Infertility in women undergoing assisted reproductive technology (ART)
- Hypogonadotropic hypogonadism in males
- Anovulation and ovulatory disorders in women
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions
- Headache
- Abdominal pain/bloating
Key clinical trials
- Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer
- Natural Cycle vs Programmed Cycle Frozen Embryo Transfer (NA)
- The Evaluation of Recombinant LH Supplementation in Patients With Suboptimal Response to Recombinant FSH Undergoing ICSI (PHASE4)
- The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET) (PHASE4)
- Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- r-LH supplementation CI brief — competitive landscape report
- r-LH supplementation updates RSS · CI watch RSS
- Sisli Hamidiye Etfal Training and Research Hospital portfolio CI